Vazkepa 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0021/G 
This was an application for a group of variations. 
08/01/2024 
SmPC 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
(supported by real time data) 
IAIN/0022/G 
This was an application for a group of variations. 
05/01/2024 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0019/G 
This was an application for a group of variations. 
08/12/2023 
n/a 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.a.4.b - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
corresponding test method 
IB/0018/G 
This was an application for a group of variations. 
29/09/2023 
n/a 
B.I.d.1.c - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Change 
to an approved stability protocol 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
N/0017 
Minor change in labelling or package leaflet not 
27/06/2023 
Labelling 
connected with the SPC (Art. 61.3 Notification) 
II/0009/G 
This was an application for a group of variations. 
16/03/2023 
n/a 
B.I.a.1.b - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a manufacturer of the AS supported 
by an ASMF 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0016 
B.II.b.3.a - Change in the manufacturing process of 
07/03/2023 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
PSUSA/10922
Periodic Safety Update EU Single assessment - 
09/02/2023 
n/a 
PRAC Recommendation - maintenance 
/202207 
icosapent ethyl 
IB/0014 
B.II.e.2.z - Change in the specification parameters 
23/11/2022 
n/a 
and/or limits of the immediate packaging of the 
finished product - Other variation 
IA/0015/G 
This was an application for a group of variations. 
22/11/2022 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IAIN/0013 
A.5.a - Administrative change - Change in the name 
21/10/2022 
and/or address of a manufacturer/importer 
responsible for batch release 
Annex II and 
PL 
IA/0011/G 
This was an application for a group of variations. 
13/10/2022 
n/a 
B.II.e.2.c - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Deletion of a non-significant 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
specification parameter (e.g. deletion of an obsolete 
parameter) 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
B.II.e.2.c - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Deletion of a non-significant 
specification parameter (e.g. deletion of an obsolete 
parameter) 
IAIN/0010 
B.II.b.2.c.1 - Change to importer, batch release 
14/09/2022 
n/a 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IA/0008 
B.II.d.2.a - Change in test procedure for the finished 
04/05/2022 
n/a 
product - Minor changes to an approved test 
procedure 
PSUSA/10922
Periodic Safety Update EU Single assessment - 
24/02/2022 
25/04/2022 
SmPC and 
Refer to Scientific conclusions and grounds recommending 
/202107 
icosapent ethyl 
Labelling 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10922/202107. 
IA/0007/G 
This was an application for a group of variations. 
04/02/2022 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0006 
B.II.e.5.a.2 - Change in pack size of the finished 
14/01/2022 
25/04/2022 
SmPC, Annex 
Annex A, SmPC, Labelling, Annex II and Package Leaflet 
product - Change in the number of units (e.g. 
II, Labelling 
have been updated to reflect change in pack size of the 
tablets, ampoules, etc.) in a pack - Change outside 
and PL 
finished product Vazkepa 1g, soft capsules to add a new 
the range of the currently approved pack sizes 
pack size of 360 (3x120) capsules EU/1/20/1524/003. 
Furthermore, MAH took opportunity to implement some 
minor editorial changes in the dossier and in the SmPC, 
Annex II and the Package Leaflet 
II/0003 
B.I.a.1.c - Change in the manufacturer of AS or of a 
07/10/2021 
n/a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer uses a substantially different 
route of synthesis or manufacturing conditions 
IAIN/0004/G 
This was an application for a group of variations. 
01/09/2021 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
II/0001 
C.I.13 - Other variations not specifically covered 
08/07/2021 
n/a 
elsewhere in this Annex which involve the submission 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of studies to the competent authority 
IAIN/0002/G 
This was an application for a group of variations. 
31/05/2021 
25/04/2022 
SmPC and PL 
To include in the Product Information the black 
symbol and explanatory statements for medicinal 
products subject to additional monitoring and to 
update section 4.1 to align the PIs with the Swedish 
translation. 
C.I.12 - Inclusion or deletion of black symbol and 
explanatory statements for medicinal products in the 
list of medicinal products that are subject to 
additional monitoring 
C.I.1.a - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a Union 
referral procedure - The product is not covered by 
the defined scope of the procedure 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
 
